Get the Stockscreener App
3.455
0.43%
-0.015
Kala Bio Inc stock is traded at $3.455, with a volume of 13,666.
It is down -0.43% in the last 24 hours and down -50.66% over the past month.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$3.47
Open:
$3.48
24h Volume:
13,666
Relative Volume:
0.24
Market Cap:
$22.52M
Revenue:
$5.75M
Net Income/Loss:
$-38.96M
P/E Ratio:
-0.2771
EPS:
-12.47
Net Cash Flow:
$-32.63M
1W Performance:
+1.02%
1M Performance:
-50.66%
6M Performance:
-32.41%
1Y Performance:
-49.47%
1-Day Range:
$3.40
$3.54
1-Week Range:
$3.35
$3.85
52-Week Range:
$3.35
$11.20
Kala Bio Inc Stock (KALA) Company Profile
Name
Kala Bio Inc
Sector
Industry
Phone
781-996-5252
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
3.455 | 22.52M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
| Jul-23-20 | Initiated | Northland Capital | Outperform |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-27-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc Stock (KALA) Latest News
Oppenheimer maintains Kala Bio stock Outperform with $15 target By Investing.com - Investing.com Canada
Kala Bio announces executive retention bonuses - Investing.com Australia
KALA stock touches 52-week low at $3.4 amid market challenges By Investing.com - Investing.com South Africa
Kala Bio announces executive retention bonuses By Investing.com - Investing.com South Africa
Kala Pharmaceuticals Announces Executive Retention Agreements - TipRanks
KALA stock touches 52-week low at $3.4 amid market challenges - Investing.com
Darling Ingredients Inc. (NYSE:DAR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Truist Financial Lowers Bank of New York Mellon (NYSE:BK) Price Target to $90.00 - Defense World
HC Wainwright Reaffirms “Buy” Rating for KALA BIO (NASDAQ:KALA) - Defense World
Kala Pharmaceuticals stock hits 52-week low at $4.05 - Investing.com India
Kala Pharmaceuticals stock hits 52-week low at $4.05 By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Kala Bio, target at $15 By Investing.com - Investing.com Canada
Kala Bio Inc Reports Q4 2024 Earnings: EPS Misses Estimate at -2 - GuruFocus
Simply Good Foods (SMPL) Expected to Announce Earnings on Wednesday - The AM Reporter
Oppenheimer maintains Outperform on Kala Pharmaceuticals stock - Investing.com Australia
Oppenheimer maintains Outperform on Kala Pharmaceuticals stock By Investing.com - Investing.com UK
KALA BIO: Q4 Earnings Snapshot - Huron Daily Tribune
KALA BIO Advances Eye Disease Therapies with New Funding - TipRanks
KALA BIO Inc. (KALA) reports earnings - Quartz
KALA BIO, Inc. SEC 10-K Report - TradingView
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - TradingView
North American Morning Briefing : Tariff Jitters -2- - Marketscreener.com
KALA BIO (KALA) Projected to Post Quarterly Earnings on Friday - Defense World
KALA BIO Inc expected to post a loss of $2.28 a shareEarnings Preview - TradingView
Comprehensive Insights of the Global Acute Ocular Pain Market: Key Drivers, Trends, Growth Opportunities, a... - WhaTech
KALA BIO (KALA) Expected to Announce Quarterly Earnings on Thursday - Defense World
Kala Bio appoints new interim CEO amid leadership shuffle - MSN
KALA BIO to Present at TD Cowen 45th Annual Health Care Conference - TradingView
BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million - The Manila Times
What Will KALA BIO Reveal at the TD Cowen Healthcare Conference Next Week? - StockTitan
Kala Bio Stock Sinks On CEO Exit, But Retail Feels It’s An Overreaction - MSN
Precision Bio stock gains on Hep B drug data (DTIL:NASDAQ) - Seeking Alpha
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth - The Manila Times
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth - GlobeNewswire
Major Leadership Shake-up: Pharma Veteran Takes Helm at Inhibikase with $110M War Chest - StockTitan
KALA BIO's (KALA) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Kala Bio Inc (NASDAQ: KALA) Has Been Trading Down. What Are The Prospects For The Future? - Stocks Register
KALA BIO says CEO Mark Iwicki resigns - MSN
Cabaletta Bio to Present at Guggenheim’s SMID Cap Biotech Conference - MSN
Kala Bio Inc Stock (KALA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):